AAAAAA

   
Results: 1-9 |
Results: 9
Breakthrough of Ac-225 and its radionuclide daughters from an Ac-225/Bi-213 generator: development of new methods, quantitative characterization, andimplications for clinical use
Authors: Ma, DH McDevitt, MR Finn, RD Scheinberg, DA
Citation: Dh. Ma et al., Breakthrough of Ac-225 and its radionuclide daughters from an Ac-225/Bi-213 generator: development of new methods, quantitative characterization, andimplications for clinical use, APPL RAD IS, 55(5), 2001, pp. 667-678
Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals
Authors: Ma, DH McDevitt, MR Finn, RD Scheinberg, DA
Citation: Dh. Ma et al., Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals, APPL RAD IS, 55(4), 2001, pp. 463-470
Tumor therapy with targeted atomic nanogenerators
Authors: McDevitt, MR Ma, DS Lai, LT Simon, J Borchardt, P Frank, RK Wu, K Pellegrini, V Curcio, MJ Miederer, M Bander, NH Scheinberg, DA
Citation: Mr. Mcdevitt et al., Tumor therapy with targeted atomic nanogenerators, SCIENCE, 294(5546), 2001, pp. 1537-1540
Response of LNCaP spheroids after treatment with an alpha-particle emitter(Bi-213)-labeled anti-prostate-specific membrane antigen antibody (J591)
Authors: Ballangrud, AM Yang, WH Charlton, DE McDevitt, MR Hamacher, KA Panageas, KS Ma, DS Bander, NH Scheinberg, DA Sgouros, G
Citation: Am. Ballangrud et al., Response of LNCaP spheroids after treatment with an alpha-particle emitter(Bi-213)-labeled anti-prostate-specific membrane antigen antibody (J591), CANCER RES, 61(5), 2001, pp. 2008-2014
An alpha-particle emitting antibody ([Bi-213]J591) for radioimmunotherapy of prostate cancer
Authors: McDevitt, MR Barendswaard, E Ma, D Lai, L Curcio, MJ Sgouros, G Ballangrud, AM Yang, WH Finn, RD Pellegrini, V Geerlings, MW Lee, M Brechbiel, MW Bander, NH Cordon-Cardo, C Scheinberg, DA
Citation: Mr. Mcdevitt et al., An alpha-particle emitting antibody ([Bi-213]J591) for radioimmunotherapy of prostate cancer, CANCER RES, 60(21), 2000, pp. 6095-6100
An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation
Authors: McDevitt, MR Finn, RD Sgouros, G Ma, DS Scheinberg, DA
Citation: Mr. Mcdevitt et al., An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation, APPL RAD IS, 50(5), 1999, pp. 895-904
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia
Authors: Sgouros, G Ballangrud, AM Jurcic, JG McDevitt, MR Humm, JL Erdi, YE Mehta, BM Finn, RD Larson, SM Scheinberg, DA
Citation: G. Sgouros et al., Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia, J NUCL MED, 40(11), 1999, pp. 1935-1946
Preparation of alpha-emitting Bi-213-labeled antibody constructs for clinical use
Authors: McDevitt, MR Finn, RD Ma, D Larson, SM Scheinberg, DA
Citation: Mr. Mcdevitt et al., Preparation of alpha-emitting Bi-213-labeled antibody constructs for clinical use, J NUCL MED, 40(10), 1999, pp. 1722-1727
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry
Authors: Nikula, TK McDevitt, MR Finn, RD Wu, CC Kozak, RW Garmestani, K Brechbiel, MW Curcio, MJ Pippin, CG Tiffany-Jones, L Geerlings, MW Apostolidis, C Molinet, R Geerlings, MW Gansow, OA Scheinberg, DA
Citation: Tk. Nikula et al., Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry, J NUCL MED, 40(1), 1999, pp. 166-176
Risultati: 1-9 |